Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 10Urinary Bladder Neoplasms 7Prostatic Neoplasms 6Breast Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Recurrence 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Hematologic Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urologic Neoplasms 1Thrombocytosis 1Stroke 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Disulfides × Genitourinary × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡